© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Moffitt Cancer Center | Association Partnerships
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
Moffitt study shows adaptive therapy improves outcomes, reduces care costs for prostate cancer patients
June 30, 2022
Article
“These analyses illustrate the critical role for inclusion of mathematical models, evolutionary first principles and computer simulations in trial design. Unlike conventional clinical trials, this approach allows both cohort and patient-specific analyses," said Jingsong Zhang, MD, PhD.
Dr. Spiess on key penile and testis cancer research from AUA 2022
June 24, 2022
Video
Philippe Spiess, MD, MS, FACS, recaps several presentations from the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana.
Moffitt researchers contribute to discovery of mechanism leading to drug resistance in prostate cancer
June 16, 2022
Article
The Moffitt research team, in collaboration with scientists at Washington University in St. Louis, wanted to identify alternative resistance mechanisms to enzalutamide and abiraterone in prostate cancer patients.
Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG
June 09, 2022
Video
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
Moffitt researchers discover new target for CAR T-Cells in solid tumors
May 26, 2022
Article
Prostate tumors are among the cancers for whom this novel therapy is being explored.